Idorsia reports 74% year-on-year QUVIVIQ sales growth in Q1 2026, reaching CHF 44 million, supported by expanding global access and strong clinical progress including positive pediatric data.
Written By: Samiksha Jadhav, BPharm
Reviewed By: Pharmacally Editorial Team
Idorsia delivered a strong start to 2026, driven by the continued momentum of QUVIVIQ (daridorexant), which is emerging as both a commercial and clinical cornerstone for the company. In the first quarter, QUVIVIQ sales increased 74% year-on-year to CHF 44 million, up from CHF 25 million in Q1 2025, making it the primary contributor to total net revenue of CHF 57 million.
This performance reflects growing adoption across North America and Europe, supported by expanding geographic reach, with the product now available in 13 countries and additional launches underway.
Reimbursement progress in key European markets such as France, Germany, the United Kingdom, and Austria, alongside broad insurance coverage in the United States, is improving patient access, although prescribing in the U.S. remains constrained by its scheduled status.
Idorsia is continuing to invest in commercial execution through co-promotion partnerships and greater use of digital and direct-to-patient channels to support further uptake and adherence.
Alongside its financial growth, QUVIVIQ’s clinical profile continues to expand, reinforcing its differentiation within the insomnia treatment landscape. Ongoing studies are exploring its use in patients with comorbid conditions such as depression, anxiety, substance use disorders, and neurodegenerative diseases, with the aim of extending its utility beyond primary insomnia.
A key highlight in the quarter is the positive Phase 2 pediatric data for daridorexant, which demonstrated a statistically significant, dose-dependent improvement in total sleep time, along with meaningful benefits across multiple sleep parameters.
The treatment was well tolerated, including at the 50 mg dose, and showed particularly strong efficacy in children with neurodevelopmental disorders, representing a potential expansion opportunity.
At the same time, Idorsia is advancing a label-enabling study focused on daytime functioning, which could further strengthen QUVIVIQ’s clinical value proposition.
Despite strong top-line growth, Idorsia remains in an investment phase, reporting a non-GAAP operating loss of CHF 24 million and a US GAAP operating loss of CHF 26 million for the quarter as it continues to fund commercial expansion and pipeline development. The company has maintained its full-year guidance of CHF 200 million in QUVIVIQ sales, indicating confidence in sustained growth throughout 2026.
With increasing market penetration, expanding clinical evidence, and ongoing lifecycle initiatives, QUVIVIQ is well positioned to evolve into a major global therapy in insomnia, supporting Idorsia’s broader ambition to achieve long-term commercial scale.
Reference
Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year
About the Writer
Samiksha Vikram Jadhav is a B. Pharm graduate with a strong academic foundation in pharmaceutical sciences, pharmacology, and drug development. She specializes in pharma market research, with a focused interest in mergers and acquisitions, strategic partnerships, and global pharma and biotech deals. Her work centers on analyzing industry transactions, market positioning, and business strategies, translating complex developments into clear, accurate, and insightful scientific and commercial reporting.